

## SoonerCare



## Zytiga<sup>®</sup>/ Yonsa<sup>®</sup> (Abiraterone) Prior Authorization Form

Member Name:	Date of Birth:	Member ID#:
Drug Information		
Pharmacy Billing (NDC:	:) Start Date (or date of next dose):	
Dose:	Regimen:	
Pharmacy Information		
Pharmacy NPI:	Pharmacy Na	me:
Pharmacy Phone:	Pharmacy Fax	C
Prescriber Information		
Prescriber NPI:	Prescriber Name:	
Prescriber Phone:	Prescriber Fax:	Specialty:
Criteria Cri		
<ol> <li>Will abiraterone be used in combination with a corticosteroid? Yes No</li> <li>Please indicate the diagnosis and information:         <ul> <li>Metastatic Castration-Resistant Prostate Cancer (CRPC)</li> <li>A. Will abiraterone be used in combination with a gonadotropin-releasing hormone (GnRH) analog? Yes No</li> <li>B. Does member have a prior history of bilateral orchiectomy? Yes No</li> <li>Metastatic Castration-Sensitive Prostate Cancer (CSPC)</li></ul></li></ol>		
For Continued Authorization:  1. Date of last dose:  2. Does patient have any evidence of progressive disease while on abiraterone therapy? Yes No  3. Has the member experienced any adverse drug reactions related to abiraterone therapy? Yes No  If yes, please specify adverse reactions:		
Prescriber Signature:		
I certify that the indicated treatment is medically necessary and all information is true and correct to the best of my knowledge. Please do not send in chart notes. Specific information will be requested if necessary. Failure to complete this form in full will result in processing delays.		

Fax completed prior authorization request form to 888-601-8461 or submit Electronic Prior Authorization through CoverMyMeds® or SureScripts. All requested data must be provided. Incomplete forms or forms without the chart notes will be returned. Pharmacy Coverage Guidelines are available at

AetnaBetterHealth.com/Oklahoma.

## **CONFIDENTIALITY NOTICE**

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.

Pharm - 56 8/21/2023